Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: A pilot study

Ruthanne Chun, Ilene D. Kurzman, C. Guillermo Couto, Jeff Klausner, Carolyn Henry, E. Gregory MacEwen

Research output: Contribution to journalArticlepeer-review

66 Scopus citations


Sixteen dogs with histologically confirmed appendicular osteosarcoma were treated by amputation followed by cisplatin and doxorubicin chemotherapy. All dogs began chemotherapy within 24 hours of surgery. Cisplatin was administered at 50 mg/m2 intravenously (IV) concurrent with saline-induced diuresis. Doxorubicin was administered 24 hours later at 15 mg/m2 as a slow IV bolus. This protocol was given on a 21-day cycle for 4 cycles. No dose delays were required, but dose reduction of doxorubicin was required in 2 dogs because of neutropenia. Thoracic radiography was performed every 2 months after completion of therapy to monitor for metastatic disease. Two dogs were still alive and free from disease at the time of last contact (24 and 75 months, respectively). Postmortem examinations were performed on 13 of the 14 dogs that died. Eight of these dogs were euthanized because of metastatic osteosarcoma. Of the remaining 5 dogs, euthanasia was performed because of complications of idiopathic megaesophagus (n = 1), arthritis (n = 2), and hemangiosarcoma (n = 2). The median disease-free interval and survival times were 15.7 and 18 months, respectively. When compared to a historical group of 36 dogs with appendicular osteosarcoma treated with surgery and 4 doses of cisplatin. both disease-free interval and overall survival were significantly longer in the study population (P < .015 and P < .007, respectively).

Original languageEnglish (US)
Pages (from-to)495-498
Number of pages4
JournalJournal of veterinary internal medicine / American College of Veterinary Internal Medicine
Issue number5
StatePublished - 2000

Fingerprint Dive into the research topics of 'Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: A pilot study'. Together they form a unique fingerprint.

Cite this